secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001493152-23-040318
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona submits BLA for pz-cel; Q3 net loss $11.8M, cash $54.1M
--------------------------------------------------------------

- Q3 net loss $11.8M ($0.48/share) vs $6.4M ($1.00/share) in Q3 2022.
- Cash and short-term investments $54.1M; estimated runway into Q4 2024.
- BLA for pz-cel (gene therapy for RDEB) submitted in September; FDA decision expected late-Nov 2023.
- Raised $25M in July registered direct offering; commercial launch prep underway.
- Appointed Madhav Vasanthavada as Chief Commercial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/0001493152-23-040318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer